NEW YORK, N.Y. – The following is a list of initial public offerings planned for the coming week. Sources include Renaissance Capital, Greenwich, CT (www.renaissancecapital.com) and SEC filings.
Week of June 16:
Ardelyx Inc. – Fremont, Calif., 3.6 million shares, priced $13 to $15, managed by Citigroup and Leerink Partners. Proposed Nasdaq symbol ARDX. Business: Biotech developing small molecule treatments for kidney and gastrointestinal diseases.
Century Communities Inc. – Greenwood Village, Colo., 4.5 million shares, priced $23 to $26, managed by FBR Capital Markets, J.P. Morgan, and Deutsche Bank. Proposed NYSE symbol CCS. Business: Single-family homebuilder primarily in Colorado, as well as Texas and Nevada.
Eclipse Resources Corp. – State College, Pa., 30.3 million shares, priced $27 to $30, managed by Citigroup, Goldman Sachs, and Morgan Stanley. Proposed NYSE symbol ECR. Business: Oil and natural gas E&P operating in the Appalachian Basin.
Foresight Energy LP – St. Louis, Mo., 17.5 million shares, priced $19 to $21, managed by Barclays, Citigroup, and Morgan Stanley. Proposed NYSE symbol FELP. Business: Spinoff of Foresight Reserves with 3 billion tons of coal reserves in the Illinois basin.
Kite Pharma Inc. – Santa Monica, Calif., 6 million shares, priced $12 to $14, managed by Jefferies, Credit Suisse, and Cowen & Co. Proposed Nasdaq symbol KITE. Business: Clinical stage biotech developing an immunotherapy cancer treatment.
Markit Ltd. – London, U.K., 45.7 million shares, priced 23 to $25, managed by BofA Merrill Lynch, Barclays, and Citigroup. Proposed Nasdaq symbol MRKT. Business: Largest provider of bond information and derivatives trade processing.
Microlin Bio Inc. – New York, 2.7 million shares, priced $10 to $12, managed by Brean Capital and Summer Street Research. Proposed Nasdaq symbol MCLB. Business: Development stage diagnostic and therapeutics company focusing on microRNA and its role in oncology. Issue was previously postponed.
Parnell Pharmaceuticals Holdings Ltd. – Alexandria, Australia, 3.6 million ordinary shares, priced $17 to $19, managed by Jefferies and Piper Jaffray. Proposed Nasdaq symbol PARN. Business: Provides drugs and health software for production and companion animals.
Syndax Pharmaceuticals Inc. – Waltham, Mass., 4.3 million shares, priced $13 to $15, managed by Deutsche Bank and Jefferies. Proposed Nasdaq symbol SNDX. Business: Late-stage biotech developing a novel therapy for treatment-resistant breast cancer.
Viper Energy Partners LP – Midland, Texas, 5 million common units, priced $19 to $21, managed by Barclays, Credit Suisse, and Wells Fargo. Proposed Nasdaq symbol VNOM. Business: Oil and gas E&P in the Permian Basin spun out of Diamondback Energy.
Zafgen Inc. – Cambridge, Mass., 5 million shares, priced $14 to $16, managed by Leerink Partners and Cowen & Co. Proposed Nasdaq symbol ZFGN. Business: Clinical-stage biotech developing treatments for severe obesity and hunger-related disorders.
ZS Pharma Inc. – Coppell, Texas, 5 million shares, priced $15 to $17, managed by J.P. Morgan and Credit Suisse. Proposed Nasdaq symbol ZSPH. Business: Late-stage biotech developing a treatment for excess potassium (hyperkalemia).